Hook / Thesis
Brown & Brown is a classic roll-up story: a large, diversified insurance broker that grows via targeted tuck-in acquisitions, cross-sells into a broad client base and converts revenue into steady free cash flow. The stock is under pressure today and sits near the 52-week low at $64.29, but recent deal flow and attractive adjusted margins argue the company is set to re-accelerate revenue and earnings as acquired businesses integrate.
My trade idea: buy at $64.29 with a $58 stop and a $80 target. The set-up pairs a contrarian entry - the shares are oversold (RSI ~29) and trading well below their 50-day and 200-day trend – with a clear fundamental catalyst: ongoing M&A that expands niche capabilities and lifts adjusted operating margins. Risk is real (employee defections, an organic revenue decline), but the balance of cash generation, margin expansion and a below-par P/B (~1.78) supports a mid-term swing to $80.
What Brown & Brown does and why it matters
Brown & Brown, Inc. is an insurance agency and specialty broker operating three segments: Retail, Specialty Distribution and Other. The firm provides brokerage, underwriting programs and services to commercial, public, professional and individual customers. With over 700 locations and roughly 22,888 employees, the company’s model is geographically diversified and scale-driven.
Why investors should care: insurance distribution is increasingly fragmented and consolidating. Brown & Brown’s playbook is to buy specialized agencies and MGAs that offer niche products, fold them into its distribution network, and extract margins through scale and cross-sell. That strategy is visible in the last 12 months of deal announcements and the financials: M&A drove total revenue to $1.6 billion in Q4 2025 (up 35.7% YoY) and full-year 2025 revenues to $5.9 billion (up 22.8%). The company reported adjusted diluted EPS of $4.26 for 2025 and adjusted margins expanded to 35.9%.
Numbers that support the thesis
- Price and market snapshot: shares are trading at $64.29, market cap roughly $21.9 billion and price-to-earnings near 21.0 (trailing) with price-to-book about 1.78.
- Revenue: total Q4 2025 revenues were $1.6 billion (up 35.7% YoY) and full-year 2025 revenue totaled $5.9 billion (up 22.8%).
- Margins and cash flow: adjusted diluted EPS of $4.26 and adjusted margins expanded to 35.9% in 2025. Free cash flow for the most recent period was $1.382 billion.
- Balance sheet: debt-to-equity is modest at about 0.61, and the company continues to pay a regular quarterly cash dividend ($0.165 per share).
How the market is seeing the setup — technicals and positioning
Technically, BRO has pulled back aggressively from last year’s peak ($125.675 on 04/01/2025) and printed a fresh 52-week low near $63.29 on 03/25/2026. Momentum indicators look stretched: RSI sits around 29.5 and the stock is below its 10-, 20- and 50-day moving averages (SMA50 ~ $71.61). Short interest has been creeping higher; the March 13 settlement showed roughly 18.08 million shares short (about 6.8 days to cover) — enough to create increased volatility if sentiment swings the other way.
Valuation framing
On a simple multiple basis, the shares trade at roughly 21x trailing earnings and ~1.8x book. Given Brown & Brown’s free cash flow generation (~$1.38B) and adjusted margin profile (35.9%), a re-rating toward a mid-20s P/E is justified if organic growth stabilizes and acquisition synergies materialize. Consider also enterprise value: EV metrics imply meaningful value capture from cash-generative insurance operations and the recurring nature of distribution revenue. Compared to its historical trading range (recent peak near $125), the current price reflects a market discount for execution risk and near-term organic weakness rather than a permanent impairment to the business model.
Catalysts to make this trade work
- Integration wins and realized synergies from Accession and other tuck-ins that were highlighted in the Q4 2025 release (results released 01/26/2026).
- Further accretive acquisitions in high-margin niches (recent deals include the Protectorate/American Adventure assets on 02/17/2026 and Shoemaker & Besser assets on 01/08/2026).
- Stabilization of organic revenue trends — reversing the reported -2.8% organic revenue decline in Q4 2025 would materially re-rate multiples.
- Positive free cash flow and continued dividend support investor confidence and provide dry powder for additional acquisitions.
Trade plan (actionable)
Entry: Buy at $64.29 (current market price).
Stop loss: $58.00. Placement below the recent low gives room for noise while protecting capital if the stock breaks structurally lower.
Target: $80.00. This target assumes partial multiple recovery (to low-mid 20s P/E) and modest revenue re-acceleration through integration and cross-sell. Risk/reward at entry is roughly 1:2.5 (down ~9.8% to stop vs up ~24.4% to target).
Horizon: Mid term (45 trading days). The primary move I expect is a mid-term swing as integration news, earnings commentary or stabilization in organic revenues triggers a re-rating. If the stock reaches $80 earlier on a short squeeze or positive headline, trim position and re-evaluate.
Position sizing and management: Treat this as a medium-conviction swing. Use a position size that limits downside to no more than 1-2% of portfolio value at the stop. If the trade goes in your favor, consider moving the stop to break-even after a 10%-12% move and scale out into strength.
Risks and counterarguments
- Execution risk on integrations: Acquisitions are Brown & Brown’s growth engine, but integrating many small deals can dilute management focus and delay cost synergies. If integration costs run higher or synergies lag, earnings could disappoint.
- Employee defections / revenue leakage: The company disclosed a meaningful defection of people and revenue earlier in 2026 (a reported incident resulted in $23 million of lost annual revenue), which triggered a securities-law inquiry announced 03/03/2026. If defections accelerate, organic revenue could remain pressured.
- Regulatory or legal noise: The Pomerantz investigation (03/03/2026) around disclosures adds headline risk and could pressure the stock until resolved.
- Macro/insurance cycle risk: Commercial insurance pricing and underwriting cycles influence broker commissions and program profitability. A softening market or adverse loss experience at a major underwritten program could dent margins.
- Counterargument: The market’s concern about organic weakness and the recent employee defections may be underestimating the company’s ability to replace ARR via tuck-ins. Brown & Brown’s recent string of purchases (Bridge Specialty Group, Wright Flood’s acquisition of Poulton Associates, American Adventure assets) shows disciplined deal flow and a history of margin accretion, arguing that short-term churn is offset by scalable acquisition economics.
What would change my mind
I would reconsider this bullish stance if any of the following occur:
- Organic revenues show persistent double-digit declines for two consecutive quarters despite acquisitions.
- Management flags material integration failures or writes down acquired goodwill/assets.
- Legal/regulatory developments from the investor litigation materially impact earnings or force a change in disclosure practices.
Conclusion
Brown & Brown looks like an asymmetric opportunity at $64.29 for a mid-term swing. The combination of continued M&A, strong adjusted margins (35.9%), and $1.382B in free cash flow provides a durable underpinning for the business. The stock is priced for disappointment today, leaving room for a re-rating if organic growth stabilizes and acquisitions continue to deliver. That said, there are real execution and legal risks that require a tight stop and disciplined position sizing.
If you take the trade, enter at $64.29, stop at $58, and target $80 with a mid-term horizon of 45 trading days. Monitor integration updates, organic revenue commentary, and legal headlines closely; any sign of persistent revenue erosion or material write-downs would force an exit or reassessment.